Muraki N, Yamada M, Doki H, Nakai R, Komeda K, Goto D, Kawabe N, Matsuoka K, Matsushima M, Kawabe T, et al. Resistance to mutant KRASV12-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line. Experimental Cell Research. 2022. 414. 1. 113053-113053
Tanaka I, Morise M. Current immunotherapeutic strategies targeting the PD-1/PD-L1 axis in non-small cell lung cancer with oncogenic driver mutations. International Journal of Molecular Sciences. 2022. 23. 1
Tanaka I, Dayde D, Tai MC, Mori H, Solis LM, Tripathi SC, Fahrmann JF, Unver N, Parhy G, Jain R, et al. SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. Journal of the National Cancer Institute. 2021. 114. 2. 290-301
Tanaka Ichidai, Furukawa Taiki, Morise Masahiro. The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. CANCER CELL INTERNATIONAL. 2021. 21. 1. 454
Matsuzawa R, Morise M, Tanaka I, Hayai S, Tamiya Y, Koyama J, Hase T, Wakahara K, Deoksu K, Shimoyama Y, et al. Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer. Internal medicine (Tokyo, Japan). 2021. 61. 5. 703-708